Ranbaxy drags Sun Pharma Q4

India’s largest drug maker by market value Sun Pharmaceuticals on Friday reported a 44% fall in consolidated net profit for the fourth quarter of 2014-15.

Net profit for the quarter stood at ` 888 crore, as against ` 1,587 crore in the year-ago period.

“Our performance has been impacted due to various onetime charges, mainly on account of the Ranbaxy merger as well as due to price erosion for some of our products in the US,” said Dilip Shanghvi, the pharma major’s managing director.

For 2014-15, the company posted a 44% growth in net profit.